BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 17686173)

  • 21. Ordered accumulation of mutations conferring resistance to sulfadoxine-pyrimethamine in the Plasmodium falciparum parasite.
    Mita T; Ohashi J; Venkatesan M; Marma AS; Nakamura M; Plowe CV; Tanabe K
    J Infect Dis; 2014 Jan; 209(1):130-9. PubMed ID: 23922363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi.
    Nkhoma S; Molyneux M; Ward S
    Acta Trop; 2007 May; 102(2):138-42. PubMed ID: 17544355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes.
    Méndez F; Herrera S; Murrain B; Gutiérrez A; Moreno LA; Manzano M; Muñoz A; Plowe CV
    Am J Trop Med Hyg; 2007 Sep; 77(3):438-43. PubMed ID: 17827356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda.
    Sendagire H; Kyabayinze D; Swedberg G; Kironde F
    Trop Med Int Health; 2005 Jun; 10(6):537-43. PubMed ID: 15941416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment.
    Eriksen J; Mwankusye S; Mduma S; Kitua A; Swedberg G; Tomson G; Gustafsson LL; Warsame M
    Trans R Soc Trop Med Hyg; 2004 Jun; 98(6):347-53. PubMed ID: 15099990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
    Bwijo B; Kaneko A; Takechi M; Zungu IL; Moriyama Y; Lum JK; Tsukahara T; Mita T; Takahashi N; Bergqvist Y; Björkman A; Kobayakawa T
    Acta Trop; 2003 Mar; 85(3):363-73. PubMed ID: 12659974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in dhfr and dhps genes of Plasmodium falciparum three years after SP withdrawal in Bahir Dar, Northwest Ethiopia.
    Hailemeskel E; Kassa M; Taddesse G; Mohammed H; Woyessa A; Tasew G; Sleshi M; Kebede A; Petros B
    Acta Trop; 2013 Dec; 128(3):636-41. PubMed ID: 24055717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya.
    Iriemenam NC; Shah M; Gatei W; van Eijk AM; Ayisi J; Kariuki S; Vanden Eng J; Owino SO; Lal AA; Omosun YO; Otieno K; Desai M; ter Kuile FO; Nahlen B; Moore J; Hamel MJ; Ouma P; Slutsker L; Shi YP
    Malar J; 2012 Jul; 11():134. PubMed ID: 22540158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso.
    Dokomajilar C; Lankoande ZM; Dorsey G; Zongo I; Ouedraogo JB; Rosenthal PJ
    Am J Trop Med Hyg; 2006 Jul; 75(1):162-5. PubMed ID: 16837725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations.
    Sridaran S; McClintock SK; Syphard LM; Herman KM; Barnwell JW; Udhayakumar V
    Malar J; 2010 Aug; 9():247. PubMed ID: 20799995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea.
    Mita T; Kaneko A; Hwaihwanje I; Tsukahara T; Takahashi N; Osawa H; Tanabe K; Kobayakawa T; Björkman A
    Infect Genet Evol; 2006 Nov; 6(6):447-52. PubMed ID: 16600696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug resistance and genetic diversity of Plasmodium falciparum parasites from suriname.
    Peek R; VAN Gool T; Panchoe D; Greve S; Bus E; Resida L
    Am J Trop Med Hyg; 2005 Nov; 73(5):833-8. PubMed ID: 16282289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology.
    Alifrangis M; Enosse S; Pearce R; Drakeley C; Roper C; Khalil IF; Nkya WM; Rønn AM; Theander TG; Bygbjerg IC
    Am J Trop Med Hyg; 2005 Feb; 72(2):155-62. PubMed ID: 15741552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia.
    Al-Farsi HM; Al-Hashami ZS; Bin Dajem SM; Al-Sheikh AA; Al-Qahtani A; Beja-Pereira A; Idris MA; Babiker HA
    Infect Genet Evol; 2012 Aug; 12(6):1253-9. PubMed ID: 22709478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo.
    Ndounga M; Tahar R; Basco LK; Casimiro PN; Malonga DA; Ntoumi F
    Trop Med Int Health; 2007 Oct; 12(10):1164-71. PubMed ID: 17956498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
    Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
    Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmodium falciparum: evaluation of a quantitative nucleic acid sequence-based amplification assay to predict the outcome of sulfadoxine-pyrimethamine treatment of uncomplicated malaria.
    Omar SA; Mens PF; Schoone GJ; Yusuf A; Mwangi J; Kaniaru S; Omer GA; Schallig HD
    Exp Parasitol; 2005 May; 110(1):73-9. PubMed ID: 15804381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haplotypes associated with resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum in two malaria endemic locations in Colombia.
    Hernández DC; Guerra AP; Cucunubá ZM; Nicholls RS; Barrera SM
    Infect Genet Evol; 2013 Aug; 18():183-90. PubMed ID: 23714094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine.
    Tahita MC; Tinto H; Erhart A; Kazienga A; Fitzhenry R; VanOvermeir C; Rosanas-Urgell A; Ouedraogo JB; Guiguemde RT; Van Geertruyden JP; D'Alessandro U
    PLoS One; 2015; 10(9):e0137440. PubMed ID: 26368675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
    Plowe CV; Cortese JF; Djimde A; Nwanyanwu OC; Watkins WM; Winstanley PA; Estrada-Franco JG; Mollinedo RE; Avila JC; Cespedes JL; Carter D; Doumbo OK
    J Infect Dis; 1997 Dec; 176(6):1590-6. PubMed ID: 9395372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.